SCHEMBL2302293

SCHEMBL2302293

CCOC(=O)CC(C)c1cc(F)c(O)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ SI P14410 1/20 0.38
▸ MGAM2 Q2M2H8 1/20 0.38
▸ PTPN11 Q06124 1/20 0.37
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 2/20 0.37
▸ HTT P42858 1/20 0.37
▸ ADRB2 P07550 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ ADRB3 P13945 1/20 0.36
▸ NLRP3 Q96P20 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ LTB4R Q15722 1/20 0.35
▸ LTB4R2 Q9NPC1 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31522451 0.84 ADRB2 (0.41) GAAALDH1A1KDM4EHTTADRB2
SCHEMBL19900011 0.80 ALDH1A1 (0.39) GAAALDH1A1KDM4EHTTNLRP3
SCHEMBL31601283 0.80 ALDH1A1 (0.39) GAAALDH1A1KDM4EHTTNLRP3
SCHEMBL1070390 0.79 HMGCR (0.42) GAAALDH1A1HTTCA1CA2
SCHEMBL3390348 0.78 NPSR1 (0.48) MGAMGAASIMGAM2ALDH1A1
SCHEMBL17262510 0.77 KDM4E (0.41) GAAALDH1A1KDM4EHTTNLRP3
SCHEMBL11376748 0.76 ATM (0.44) GAAALDH1A1KDM4ETSHRLMNA
SCHEMBL12836547 0.76 MAPT (0.45) LMNAMAPT
SCHEMBL987559 0.76 MAPT (0.45) LMNAMAPT
SCHEMBL3665975 0.76 KMT2A (0.49) MGAMGAASIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690095-A1 Aryl gpr120 receptor agonists and uses thereof Camabay Therapeutics, Inc. (US) 2014-01-29 — — EP disclosed
EP-2690095-A1 Aryl gpr120 receptor agonists and uses thereof Camabay Therapeutics, Inc. (US) 2014-01-29 — — EP disclosed
EP-2350016-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF Metabolex Inc. (US) 2011-08-03 — — EP disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 — — US disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 — — US disclosed
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. 2010-08-26 — — US disclosed
WO-2010048207-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-04-29 — — WO disclosed
WO-2010048207-A2 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF METABOLEX, INC. (US) 2010-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216827-A1 ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF GPR119, GPR52, GCGR MGAM 1177/4885GAA 573/4885SI 3035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback